The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/day) in Subjects with Major Depressive Disorder
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/Day) in Subjects With Major Depressive Disorder
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary diagnosis of Major Depressive Disorder (MDD)
must have met DSM-IV criteria for current major depressive episode for at least 8 weeks but no long than 2 years.
HAM-D17 total score of >17 at screening and baseline.
Severity of illness score of >4 at screening and baseline.
Willing to discuss sexual functioning with investigator or designee.
Sexual activity that leads to orgasm at least every 2 weeks.
Past or current DSM-IV diagnosis of Bipolar Disorder I or II, schizophrenia or another psychotic disorder(s).
Primary DSM-IV diagnosis or received treatment for Panic Disorder, Obsessive Compulsive Disorder or Post Stress Disorder within previous 12 months.
Poses a homicidal or serious suicidal risk, have made an attempt within months prior to screening or who has ever been homicidal.
Myocardial infarction with 1 year of screening.
Taken ibupropion hydrochloride or venlafaxine in the last 6 months.
Positive urine test for illicit drug use or alcohol or substance abuse within the past 12 months.
Psychotherapy within 3 months.
Electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior of screening.
ECG or clinical evidence of atrial or ventricular hypertrophy.